Clinical trial sharing: What are the effects of taking Opicapone?

As a new generation of long-acting COMT inhibitors, Opicapone has demonstrated excellent efficacy and good safety in multiple clinical trials around the world, especially in improving the "off-period" symptoms of patients with Parkinson's disease (PD).

A pivotalBIPARK-1 Phase III clinical trial evaluated the efficacy of opicapone in patients with Parkinson's disease. A total of more than 600 PD patients with obvious "off period" were included in the study. On the basis of receiving levodopa/dopa decarboxylase inhibitor (levodopa/DDCI), they were randomly assigned to receive opicapone (5mg, 25mg or 50mg) or placebo. The results showed that compared with the placebo, the average daily "off period" of patients in the 50 mg Opicapone group was significantly shortened by more than 60 minutes, and the motor symptom scores were significantly improved. In addition, Opicapone did not increase patients' risk of liver toxicity, and most side effects were mild, such as insomnia, mild hallucinations, or movement disorders.

Another follow-up studyBIPARK-2 once again confirmed the efficacy of opicapone and directly compared it with the traditional COMT inhibitor Entacapone. The results showed that the efficacy of the opicapone 50 mg group was significantly better than that of entacapone, and the patients' average daily medication frequency was reduced, improving compliance. These data further establish the advantages of opicapone in the adjuvant treatment of Parkinson's disease.

In addition, long-term open-label studies of Opicapone have shown that continuous use of Opicapone can maintain the efficacy for more than one year, and the patient's quality of life is significantly improved. In real-world data, opicapone was well tolerated, with only a few patients discontinuing treatment due to adverse effects.

Overall, the clinical trial results fully prove the clinical value of Opicapone in patients with Parkinson's disease, especially suitable for patients with obvious fluctuations in the "off period". In clinical application, doctors usually recommend starting with a dose of 50 mg and adjusting the levodopa dose according to the patient's individual response to optimize the treatment plan.

Reference materials:https://www.ongentys.com/